Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Sikiric et al., 2003
CT-388 and CT-868, developed by Carmot Therapeutics, are GIPR/GLP-1R agonists under investigation in obese patients, including those with type 1 diabetes (NCT04838405, NCT06062069)
- Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation, or registration as a 503A or 503B facility
Long-term hyperglycemia is strongly associated with microvascular damage, i.e., neuropathy, nephropathy, and retinopathy, which reduce life expectancy, microvascular complications, and other aspects of quality of life (Singh et al., 2025)
GLP-1 innovation vector (4): Digital integration and adherence Pharma is increasingly moving closer to patients
increase gradually to avoid bloating Hydration matters more with GLP-1s because the medication can suppress thirst especially in Las Vegas heat Lab monitoring for B12, vitamin D, and calcium is important when food intake drops significantly Medically supervised programs outperform self-directed approaches the monthly check-ins are where dose adjustments and nutrition course-corrections happen What Is the GLP-1 Diet
